Some of the most high-profile acquisitions in recent years have involved women-fronted biotechs. BioSpace reviews five of the most notable here.

Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations ...

AbbVie ABBV has been actively ramping up its deal-making efforts lately, thereby strengthening its pipeline. While immunology ...

Sanofi’s SNY stock has been trading below its 200-day and 50-day moving averages since early June. On June 23, the stock’s closing price of $48.18 was below its 50-day moving average of $50.32 and the ...

Investor interest in Sanofi’s agreement with Ventyx ratcheted up last month when the French drugmaker bought Vigil Neuroscience.

Expanding its focus on neurodegenerative diseases, Sanofi plans to acquire Vigil Neuroscience in a deal worth up to 570 million dollars. The move brings VG-3927, a potential Alzheimer’s treatment, ...

French drugmaker Sanofi said Thursday it will acquire Vigil Neuroscience, a U.S.-based biotech company focused on neurodegenerative diseases, for up to $600 million, in a move to bolster its neurology ...

Sanofi plans to acquire Vigil Neuroscience for $8 per share in cash, with an additional $2 in contingent value rights, valuing the company at approximately $470 million. This acquisition includes ...

Sanofi, an innovative global healthcare company, announced that it has entered into an agreement to acquire Vigil Neuroscience, Inc. (Vigil), a publicly traded clinical-stage biotechnology company ...

Sanofi, an innovative global healthcare company, announced that it has entered into an agreement to acquire Vigil Neuroscience, Inc. (Vigil), a publicly traded clinical-stage biotechnology company ...

About a year after investing in Vigil Neuroscience Inc., Sanofi is now acquiring the Watertown biotech and its treatment in development for Alzheimer’s disease.

Sanofi's latest acquisition shows its commitment to expanding in the neurological disease arena, capitalizing on Vigil's cutting-edge innovations. This deal sparked a rally in Vigil's stock, with ...